The FTC alleged that the transaction would create a monopoly as it would "reduce competition significantly and allow the combined Phoebe/Palmyra to raise prices for general acute-care hospital services charged to commercial health plans, substantially harming patients and local employers and employees".
联邦贸易委员会称，交易将产生垄断，因为它将“显着减少竞争，并允许Phoebe/Palmyra组合体提高对商业健康计划收取的普通急性医院服务的价格，严重伤害患者、当地雇主和雇员。